Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment

Molecular Cancer Therapeutics

Volumn 1, Issue 10, 2002, Pages 851-860

  Hayashi, Toshiaki ^a   Hideshima, Teru ^a   Akiyama, Masaharu ^a   Richardson, Paul ^a   Schlossman, Robert L ^a   Chauhan, Dharminder ^a   Munshi, Nikhil C ^a   Waxman, Samuel ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 9; DNA BINDING PROTEIN; ENDOTHELIAL CELL GROWTH FACTOR; GROWTH INHIBITOR; INTERLEUKIN 6; LYMPHOKINE; ORGANOARSENIC DERIVATIVE; OXIDE; SIGNAL PEPTIDE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; VASCULOTROPIN; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL CULTURE; CELL DIVISION; CELL NUCLEUS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; METABOLISM; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BONE MARROW CELLS; CASPASE 9; CASPASES; CELL ADHESION; CELL DIVISION; CELL NUCLEUS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ENDOTHELIAL GROWTH FACTORS; ENZYME ACTIVATION; FLOW CYTOMETRY; GROWTH INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; LYMPHOKINES; MULTIPLE MYELOMA; OXIDES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036690367     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataille, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med., 335: 91-97, 1996. (Pubitemid 26240110)
2. Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B., and Crowley, J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93: 55-65, 1999. (Pubitemid 29019388)
3. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., and Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341: 1565-1571, 1999.
4. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y. T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I., and Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96: 2943-2950, 2000.
5. Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y. T., Lin, B., Lentzsch, S., Davies, F. E., Chauhan, D., Schlossman, R. L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D. I., and Anderson, K. C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (Baltimore), 15: 1950-1961, 2001. (Pubitemid 33115003)
6. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 91: 4082-4085, 1994. (Pubitemid 24139577)
7. Podar, K., Tai, Y. T., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P., and Anderson, K. C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 98: 428-435, 2001.
8. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y. T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I., and Anderson, K. C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98: 210-216, 2001.
9. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., and Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 61: 3071-3076, 2001. (Pubitemid 32691956)
10. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
11. 3 exerts dose-dependent dual effects on APL cells. Blood, 89: 3345-3353, 1997.
12. Wang, Z. G., Rivi, R., Delva, L., Konig, A., Scheinberg, D. A., Gambacorti-Passerini, C., Gabrilove, J. L., Warrell, R. P., Jr., and Pandolfi, P. P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR independent manner. Blood, 92: 1497-1504, 1998. (Pubitemid 28406851)
13. Zhu, X. H., Shen, Y. L., Jing, Y. K., Cai, X., Jia, P. M., Huang, Y., Tang, W., Shi, G. Y., Sun, Y. P., Dai, J., Wang, Z. Y., Chen, S. J., Zhang, T. D., Waxman, S., Chen, Z., and Chen, G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. (Bethesda), 91: 772-778, 1999. (Pubitemid 29239056)
14. Perkins, C., Kim, C. N., Fang, G., and Bhalla, K. N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood, 95: 1014-1022, 2000. (Pubitemid 30062726)
15. Konig, A., Wrazel, L., Warrell, R. P., Jr., Rivi, R., Pandolfi, P. P., Jakubowski, A., and Gabrilove, J. L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood, 90: 562-570, 1997. (Pubitemid 27299095)
16. Rousselot, P., Labaume, S., Marolleau, J. P., Larghero, J., Noguera, M. H., Brouet, J. C., and Fermand, J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res., 59: 1041-1048, 1999. (Pubitemid 29135964)
17. Park, W. H., Seol, J. G., Kim, E. S., Hyun, J. M., Jung, C. W., Lee, C. C., Kim, B. K., and Lee, Y. Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res., 60: 3065-3071, 2000. (Pubitemid 30395836)
18. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Krett, N., Halgren, R., Rosen, S., Kufe, D., Kharbanda, S., and Anderson, K. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J. Biol. Chem., 272: 29995-29997, 1997. (Pubitemid 27512191)
19. Chauhan, D., Hideshima, T., Rosen, S., Reed, J. C., Kharbanda, S., and Anderson, K. C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem., 276: 24453-24456, 2001.
20. Hallek, M., Bergsagel, P. L., and Anderson, K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91: 3-21, 1998. (Pubitemid 28018724)
21. Tricot, G. New insights into role of microenvironment in multiple myeloma. Lancet, 355: 248-250, 2000. (Pubitemid 30068513)
22. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999. (Pubitemid 29102494)
23. Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., and Anderson, K. C. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene, 20: 4519-4527, 2001. (Pubitemid 32772434)
24. Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., and Anderson, K. C. Interleukin-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol., 159: 2212-2221, 1997. (Pubitemid 127681011)
25. Hideshima, T., Chauhan, D., Teoh, G., Raje, N., Treon, S. P., Tai, Y. T., Shima, Y., and Anderson, K. C. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin. Cancer Res., 6: 1180-1189, 2000. (Pubitemid 30159383)
26. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., and Epstein, J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84: 3063-3070, 1994. (Pubitemid 24328099)
27. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-255, 1995.
28. Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F. E., Shima, Y., Tai, Y. T., Rosen, S., Avraham, S., Kharbanda, S., and Anderson, K. C. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem., 275: 27845-27850, 2000.
29. Tai, Y. T., Teoh, G., Shima, Y., Chauhan, D., Treon, S. P., Raje, N., Hideshima, T., Davies, F. E., and Anderson, K. C. Isolation and characterization of human multiple myeloma cell enriched populations. J. Immunol. Methods, 235: 11-19, 2000. (Pubitemid 30089779)
30. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res., 61: 5432-5440, 2001.
31. Thornberry, N. A., and Lazebnik, Y. Caspases: enemies within. Science (Wash. DC), 281: 1312-1316, 1998. (Pubitemid 28406817)
32. Wickremasinghe, R. G., and Hoffbrand, A. V. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood, 93: 3587-3600, 1999. (Pubitemid 29249803)
33. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999. (Pubitemid 29077388)
34. Puthier, D., Bataille, R., and Amiot, M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol., 29: 3945-3950, 1999.
35. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S., and Anderson, K. C. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 15: 837-843, 1997. (Pubitemid 27390136)
36. Ward, A. C., Touw, I., and Yoshimura, A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood, 95: 19-29, 2000. (Pubitemid 30017220)
37. Uchiyama, H., Barut, B. A., Mohrbacher, A. F., Chauhan, D., and Anderson, K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82: 3712-3720, 1993. (Pubitemid 24006055)
38. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T. A., and Anderson, K. C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood, 87: 1104-1112, 1996. (Pubitemid 26043538)
39. Seol, J. G., Park, W. H., Kim, E. S., Jung, C. W., Hyun, J. M., Lee, Y. Y., and Kim, B. K. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int. J. Oncol., 18: 249-255, 2001.
40. Kitamura, K., Minami, Y., Yamamoto, K., Akao, Y., Kiyoi, H., Saito, H., and Naoe, T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia (Baltimore), 14: 1743-1750, 2000.
41. Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G., and Waxman, S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 94: 2102-2111, 1999. (Pubitemid 29430427)
42. Dai, J., Weinberg, R. S., Waxman, S., and Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93: 268-277, 1999. (Pubitemid 29019412)
43. Cai, X., Shen, Y. L., Zhu, Q., Jia, P. M., Yu, Y., Zhou, L., Huang, Y., Zhang, J. W., Xiong, S. M., Chen, S. J., Wang, Z. Y., Chen, Z., and Chen, G. Q. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia (Baltimore), 14: 262-270, 2000. (Pubitemid 30095381)
44. El-Sabban, M. E., Nasr, R., Dbaibo, G., Hermine, O., Abboushi, N., Quignon, F., Ameisen, J. C., Bex, F., de The, H., and Bazarbachi, A. Arsenic-interferon-α-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-κB activation. Blood, 96: 2849-2855, 2000.
45. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C., and Lichtenstein, A. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res., 58: 256-262, 1998. (Pubitemid 28047064)
46. Puthier, D., Derenne, S., Barille, S., Moreau, P., Harousseau, J. L., Bataille, R., and Amiot, M. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol., 107: 392-395, 1999. (Pubitemid 29530231)
47. Adams, J. M., and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science (Wash. DC), 281: 1322-1326, 1998. (Pubitemid 28406819)
48. Zhou, P., Qian, L., Kozopas, K. M., and Craig, R. W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood, 89: 630-643, 1997. (Pubitemid 27051700)
49. Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., and Reed, J. C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 91: 991-1000, 1998. (Pubitemid 28078303)
50. Hideshima, T., Nakamura, N., Chauhan, D., and Anderson, K. C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20: 5991-6000, 2001. (Pubitemid 32955041)
51. Tu, Y., Gardner, A., and Lichtenstein, A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res., 60: 6763-6770, 2000.
52. Ihle, J. N. STATs: signal transducers and activators of transcription. Cell, 84: 331-334, 1996. (Pubitemid 26058558)
53. Darnell, J. E., Jr. STATs and gene regulation. Science (Wash. DC), 277: 1630-1635, 1997.
54. Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L., Warrell, R. P., Jr., and Rafii, S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 96: 1525-1530, 2000.
55. Chomarat, P., Banchereau, J., Davoust, J., and Palucka, A. K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol., 1: 510-514, 2000.
56. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med, 2: 1096-1103, 1996. (Pubitemid 26338628)
57. Deaglio, S., Canella, D., Baj, G., Arnulfo, A., Waxman, S., and Malavasi, F. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells. Leuk. Res., 25: 227-235, 2001. (Pubitemid 32157020)
58. Hussein, M. A., Mason, J., Ravandi, F., and Rifkin, R. M. A Phase II clinical study of arsenic trioxide (ATO) in patients (Pts) with relapsed or refractory multiple myeloma (MM); a preliminary report. Blood, 98: 378a, 2001. (Pubitemid 33787687)
59. 3) and ascorbic acid (AA) in relapsed and chemorefractory multiple myeloma. Blood, 98: 375a, 2001.